1. Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali
- Author
-
Kassoum, Kayentao, Aissata, Ongoiba, Anne C, Preston, Sara A, Healy, Safiatou, Doumbo, Didier, Doumtabe, Abdrahamane, Traore, Hamadi, Traore, Adama, Djiguiba, Shanping, Li, Mary E, Peterson, Shinyi, Telscher, Azza H, Idris, Neville K, Kisalu, Kevin, Carlton, Leonid, Serebryannyy, Sandeep, Narpala, Adrian B, McDermott, Martin, Gaudinski, Siriman, Traore, Hamidou, Cisse, Mamadou, Keita, Jeff, Skinner, Zonghui, Hu, Amatigué, Zéguimé, Adama, Ouattara, M'Bouye, Doucoure, Amagana, Dolo, Abdoulaye, Djimdé, Boubacar, Traore, Robert A, Seder, and Peter D, Crompton
- Subjects
Adult ,Antimalarials ,Artemether, Lumefantrine Drug Combination ,Plasmodium falciparum ,Headache ,Humans ,General Medicine ,Malaria, Falciparum ,Mali ,Antibodies, Monoclonal, Humanized - Abstract
CIS43LS is a monoclonal antibody that was shown to protect against controlledWe conducted a phase 2 trial to assess the safety and efficacy of a single intravenous infusion of CIS43LS againstIn Part B, 330 adults underwent randomization; 110 were assigned to each trial group. The risk of moderate headache was 3.3 times as high with 40 mg of CIS43LS per kilogram as with placebo.CIS43LS was protective against
- Published
- 2022